Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy

This study is currently recruiting participants.
Verified August 2011 by Taichung Veterans General Hospital
Sponsor:
Information provided by (Responsible Party):
Taichung Veterans General Hospital
ClinicalTrials.gov Identifier:
NCT01424761
First received: August 24, 2011
Last updated: August 26, 2011
Last verified: August 2011
  Purpose

Cardiovascular disease (CVD) is the leading cause of Taiwan. American Heart Association (AHA) indicated that CVD patients with Statin therapy would decrease the recurrence of CVD. The goal for lipid lowering in CVD patients was set at the level of low-density lipoprotein cholesterol (LDL-C) below 100 mg/dL. Coenzyme Q10 is recognized as a lipid soluble antioxidant, Statin treatment might affect the level of coenzyme Q10. Therefore, the purposes of this study are going to investigate the relation of coenzyme Q10 with other antioxidant vitamins (Vitamin A, C, and E), the markers of lipid peroxidation, antioxidant enzymes activities, and the inflammatory markers in coronary artery disease (CAD) patients during Statin therapy. The study is going to design a placebo-controlled study. The investigators will recruit coronary artery disease (CAD) patients who are identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery, and healthy subjects. CAD subjects which recruit form the first year are dived into two groups by LDL-C level (LDL-C < 100 mg/dL and 100-130 mg/dL), than randomly assign to placebo and coenzyme Q10 supplements (150 mg/bid = 300 mg/d) groups (n = 20/group). Intervention is going to administration for six months. Fasting blood will be obtained in each month and determine the concentration of antioxidant vitamins, lipid peroxidation markers, antioxidant enzymes activities after intervention. Meanwhile, the investigators will measure the level of inflammatory markers in all subjects of this study. Hopefully, the results of this study could provide information of coenzyme Q10 supplementation for clinical dietitian in advising CAD patients who are under Statin therapy.


Condition Intervention Phase
Coronary Artery Disease
Dietary Supplement: Coenzyme Q10
Other: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Taichung Veterans General Hospital:

Primary Outcome Measures:
  • Antioxidant and inflammation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The study are going to measure the concentrations of coenzyme Q10, vitamin A, C, E, lipid peroxidation markers (TBARS, ox-LDL, F2-isoprostane and 8-OHdG) and antioxidant enzymes activities (TEAC, catalase, glutathione peroxidase, glutathione reductase and superoxide dismutase), and the level of inflammatory markers (hs-CRP, TNF-alfa, IL-1, IL-6 and adiponectin, ICAM-1, VCAM-1) in all subjects of this study.


Estimated Enrollment: 100
Study Start Date: August 2011
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Placebo
Placebo:starch
Other: Placebo
Placebo :starch
Other Name: Placebo
Experimental: Coenzyme Q10 Dietary Supplement: Coenzyme Q10
Coenzyme Q10 300 mg/d (150 mg/bid)
Other Name: Ubquionine

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

CAD patients is identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery and under statin therapy.

Exclusion Criteria:

  • age < 18 years old
  • pregnancy women
  • taking antioxidant vitamins supplements
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01424761

Contacts
Contact: Ping-Ting Lin, Ph.D. +886-4-24730022 ext 12187 apt810@csmu.edu.tw

Locations
Taiwan
Taichung Verterans General Hospital Recruiting
Taichung, Taiwan
Contact: Ping-Ting Lin, Ph.D.     +886-4-24730022 ext 12187     apt810@csmu.edu.tw    
Sponsors and Collaborators
Taichung Veterans General Hospital
  More Information

No publications provided

Responsible Party: Taichung Veterans General Hospital
ClinicalTrials.gov Identifier: NCT01424761     History of Changes
Other Study ID Numbers: S10241
Study First Received: August 24, 2011
Last Updated: August 26, 2011
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Coenzyme Q10
Ubiquinone
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins

ClinicalTrials.gov processed this record on May 23, 2013